Drug delivery via nano-, micro and macroporous coronary stent surfaces

Expert Opinion on Drug Delivery

Volumn 4, Issue 3, 2007, Pages 287-295

  Tsujino, Ichizo ^a   Ako, Junya ^a   Honda, Yasuhiro ^a   Fitzgerald, Peter J ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Coronary intervention; Coronary stent; Porous surface; Restenosis

Indexed keywords

ALLOY; COBALT; NANOMATERIAL; PACLITAXEL; PIMECROLIMUS; POLYMER; RAPAMYCIN; STAINLESS STEEL; TACROLIMUS;

CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; HUMAN; MATERIAL COATING; NONHUMAN; POROSITY; REVIEW;

ANIMALS; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; DRUG DELIVERY SYSTEMS; HUMANS; NANOSTRUCTURES; POROSITY; STENTS;

EID: 34248643139     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.4.3.287     Document Type: Review

References (37)

1. SERRUYS PW, DE JAEGERE P, KIEMENEIJ F et al.: A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N. Engl. J. Med. (1994) 331(8):489-495.
2. FISCHMAN DL, LEON MB, BAIM DS et al.: A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N. Engl. J. Med. (1994) 331(8):496-501.
3. KUTRYK MJ, FOLEY DP, VAN DEN BRAND M et al.: Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of Antisense DNA using Local Delivery and IVUS after Coronary Stenting (ITALICS) trial. J. Am. Coll. Cardiol. (2002) 39(2):281-287.
4. HOLMES DR, Jr, SAVAGE M, LABLANCHE JM et al.: Results of Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation (2002) 106(10):1243-1250.
5. WILENSKY RL, TANGUAY JF, ITO S et al.: Heparin infusion prior to stenting (HIPS) trial: final results of a prospective, randomized, controlled trial evaluating the effects of local vascular delivery on intimal hyperplasia. Am. Heart J. (2000) 139(6):1061-1070.
6. MORICE MC, SERRUYS PW, SOUSA JE et al.: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. (2002) 346(23):1773-1780.
7. MOSES JW, LEON MB, POPMA JJ et al.: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. (2003) 349(14):1315-1323.
8. SCHOFER J, SCHLUTER M, GERSHLICK AH et al.: Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet (2003) 362(9390):1093-1099.
9. SCHAMPAERT E, COHEN EA, SCHLUTER M et al.: The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J. Am. Coll. Cardiol. (2004) 43(6):1110-1115.
10. STONE GW, ELLIS SG, COX DA et al.: A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. (2004) 350(3):221-231.
11. COLOMBO A, DRZEWIECKI J, BANNING A et al.: Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation (2003) 108(7):788-794.
12. LANSKY AJ, COSTA RA, MINTZ GS et al.: Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation (2004) 109(16):1948-1954.
13. FINN AV, KOLODGIE FD, HARNEK J et al.: Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation (2005) 112(2):270-278.
14. NEBEKER JR, VIRMANI R, BENNETT CL et al.: Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J. Am. Coll. Cardiol. (2006) 47(1):175-181.
15. VIRMANI R, GUAGLIUMI G, FARB A et al.: Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation (2004) 109(6):701-705.
16. VAN DER GIESSEN WJ, LINCOFF AM, SCHWARTZ RS et al.: Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation (1996) 94(7):1690-1697.
17. MCFADDEN EP, STABILE E, REGAR E et al.: Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet (2004) 364(9444):1519-1521.
18. SERRUYS PW, SIANOS G, ABIZAID A et al.: The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J. Am. Coll. Cardiol. (2005) 46(2):253-260.
19. MEHILLI J, KASTRATI A, WESSELY R et al.: Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation (2006) 113(2):273-279.
20. WESSELY R, HAUSLEITER J, MICHAELIS C et al.: Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler. Thromb. Vasc. Biol. (2005) 25(4):748-753.
21. HAUSLEITER J, KASTRATI A, WESSELY R et al.: Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur. Heart J. (2005) 26(15):1475-1481.
22. WIENEKE H, DIRSCH O, SAWITOWSKI T et al.: Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. Catheter Cardiovasc. Interv. (2003) 60(3):399-407.
23. GRUBE E: Final tacrolimus outcomes in native coronaries and saphenous vein grafts: PRESENT & EVIDENT. American College of Cardiology meeting. Chicago, USA (March 2003).
24. GALLONI MR, SANTARELLI A, PASQUINO E: Preclinical results of the tacrolimus-eluting Janus carbostent. Transcatheter Cardiovascular Therapeutics. Washington DC, USA (2004).
25. FINKELSTEIN A, MCCLEAN D, KAR S et al.: Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation (2003) 107(5):777-784.
26. SERRUYS PW: The new CoStar™ stent: 12 month results with the new DES technology. European Paris Course on Revascularization. Paris, France (2005).
27. STONE GW, MOSES JW, ELLIS SG et al.: Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N. Engl. J. Med. (2007) 356(10):998-1008.
28. LAGERQVIST B, JAMES SK, STENESTRAND U et al.: Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N. Engl. J. Med. (2007) 356(10):1009-1019.
29. PFISTERER M, BRUNNER-LA ROCCA HP, BUSER PT et al.: Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol. (2006) 48(12):2584-2591.
30. TAMAI H, IGAKI K, KYO E et al.: Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation (2000) 102(4):399-404.
31. LABINAZ M, ZIDAR JP, STACK RS, PHILLIPS HR: Biodegradable stents: the future of interventional cardiology? J. Interv. Cardiol. (1995) 8(4):395-405.
32. HEUBLEIN B, ROHDE R, KAESE V et al.: Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart (2003) 89(6):651-656.
33. VOGT F, STEIN A, RETTEMEIER G et al.: Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur. Heart J. (2004) 25(15):1330-1340.
34. ZILBERMAN M, EBERHART RC: Drug-eluting bioresorbable stents for various applications. Annu. Rev. Biomed. Eng. (2006) 8:153-180.
35. MAROIS Y, SIGOT-LUIZARD MF, GUIDOIN R: Endothelial cell behavior on vascular prosthetic grafts: effect of polymer chemistry, surface structure, and surface treatment. ASAIO J (1999) 45(4):272-280.
36. GOLDEN MA, HANSON SR, KIRKMAN TR, SCHNEIDER PA, CLOWES AW: Healing of polytetrafluoroethylene arterial grafts is influenced by graft porosity. J. Vasc. Surg. (1990) 11(6):838-844; discussion 845.
37. AKERS DL, DU YH, KEMPCZINSKI RF: The effect of carbon coating and porosity on early patency of expanded polytetrafluoroethylene grafts: an experimental study. J. Vasc. Surg. (1993) 18(1):10-15.